Top 20 biopharma market caps fall 5.7% amid industry challenges
The biopharmaceutical industry faces headwinds from the Trump administration’s ongoing tariffs and drug pricing pressures in the US. As a …
Post
-
-
Trump tasks FDA to crack down on misleading drug advertising
US President Donald Trump is launching an enforcement drive against pharmaceutical companies and social media influencers who are responsible for …
-
Capricor refutes FDA’s DMD deramiocel rejection in public statement
Capricor Therapeutics has publicised a statement addressing the US Food and Drug Administration’s (FDA) decision to reject its Duchenne muscular …
-
Novo Nordisk slashes 11% of workforce as Eli Lilly pressure tightens
Novo Nordisk will cut 9,000 jobs as part of a savings plan as the drugmaker fails to grapple with the …
-
Kytopen and BlueWhale Bio partner for cell therapy innovation
Kytopen, a provider of continuous flow cellular engineering technologies, has collaborated with BlueWhale Bio to advance the manufacturing process of …
-
Health Canada approves Medison and Ipsen’s Bylvay to treat ALGS
Health Canada has approved Medison Pharma and Ipsen’s Bylvay (odevixibat) to treat cholestatic pruritus in patients aged 12 months and …
-
Novartis snaps up promising ASCVD asset with Tourmaline acquisition
Swiss pharma giant Novartis has agreed to acquire clinical-stage biopharmaceutical company Tourmaline Bio for $1.4bn. Through this deal, Novartis will expand …
-
US Government signs $56m smallpox/mpox vaccine order despite political disarray
The US Government has ordered $56m worth of mpox/smallpox vaccines to bolster public health preparedness, despite wider uncertainty in the …
-
Novo’s Ozempic price cut expected to slow market share erosion
Novo Nordisk’s decision to significantly reduce the price of blockbuster drug semaglutide is expected to slow the shift of patients …
-
Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage
Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia …
-
Servier to acquire potential Fragile X syndrome treatment from Kaerus
Servier has agreed to acquire Medicxi company Kaerus Bioscience's potential Fragile X syndrome (FXS) treatment, KER-0193. Servier will pay Kaerus Bioscience …
-
Epigenic raises $60m for epigenetic treatment development
China’s Epigenic Therapeutics has completed a Series B funding round, raising $60m to support the clinical development of its epigenetic …
-
WHO adds GLP-1RAs to essential medicines list
The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and …
-
MD Anderson and Phoenix to advance cell and gene therapy tech
The University of Texas MD Anderson Cancer Center in the US and Phoenix SENOLYTIX have announced a worldwide cross-licensing agreement …
-
Hengrui Pharma signs deal with Braveheart Bio for HRS-1893
Hengrui Pharma has agreed with US-based Braveheart Bio, which specialises in cardiovascular diseases, granting it an exclusive licence for its …
